Suchergebnisse - "ErbB-2"

Refining HER2-Negative breast cancer: distinct survival profiles of HER2-Low and HER2-Ultralow tumors.

Autoren: Leão de Alencar DE Guimarães GR Roehe AV

Quelle: Pathology, research and practice [Pathol Res Pract] 2025 Oct; Vol. 274, pp. 156140. Date of Electronic Publication: 2025 Aug 06.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Gustav Fischer Verlag Country of Publication: Germany NLM ID: 7806109 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1618-0631 (Electronic) Linking ISSN: 03440338 NLM ISO Abbreviation: Pathol Res Pract Subsets: MEDLINE

MeSH-Schlagworte: Receptor, ErbB-2*/metabolism , Receptor, ErbB-2*/analysis , Breast Neoplasms*/pathology , Breast Neoplasms*/mortality , Breast Neoplasms*/metabolism , Biomarkers, Tumor*/analysis, Humans ; Female ; Middle Aged ; Retrospective Studies ; Adult ; Aged ; Prognosis ; Immunohistochemistry ; Aged, 80 and over

mRNA nanomedicine reprograms the cell cycle to increase the effectiveness of targeted therapy for HER2-low breast cancers.

Autoren: Wang NN Luo R Ji ZH et al.

Quelle: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2025 Dec 10; Vol. 388 (Pt 2), pp. 114383. Date of Electronic Publication: 2025 Nov 01.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8607908 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4995 (Electronic) Linking ISSN: 01683659 NLM ISO Abbreviation: J Control Release Subsets: MEDLINE

MeSH-Schlagworte: Receptor, ErbB-2*/genetics , Receptor, ErbB-2*/metabolism , Breast Neoplasms*/drug therapy , Breast Neoplasms*/genetics , Breast Neoplasms*/pathology , Breast Neoplasms*/therapy , Breast Neoplasms*/metabolism , Nanoparticles*/administration & dosage , Nanoparticles*/chemistry , RNA, Messenger*/administration & dosage, Humans ; Female ; Animals ; Cell Line, Tumor ; Cell Cycle/drug effects ; Nanomedicine ; Trastuzumab/administration & dosage ; Trastuzumab/therapeutic use ; Tumor Suppressor Protein p53/genetics ; Mice ; Xenograft Model Antitumor Assays ; Lipids/chemistry

Molecular profiling of the Basal-like intrinsic molecular subtype in primary ER-positive HER2-negative breast cancer.

Autoren: Hohmann L Nacer DF Aine M et al.

Quelle: Genome medicine [Genome Med] 2025 Dec 01; Vol. 17 (1), pp. 146. Date of Electronic Publication: 2025 Dec 01.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: BioMed Central Country of Publication: England NLM ID: 101475844 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-994X (Electronic) Linking ISSN: 1756994X NLM ISO Abbreviation: Genome Med Subsets: MEDLINE

MeSH-Schlagworte: Receptor, ErbB-2*/metabolism , Receptor, ErbB-2*/genetics , Receptors, Estrogen*/metabolism , Receptors, Estrogen*/genetics , Breast Neoplasms*/genetics , Breast Neoplasms*/pathology , Breast Neoplasms*/metabolism , Biomarkers, Tumor*/genetics, Humans ; Female ; DNA Methylation ; Middle Aged ; Triple Negative Breast Neoplasms/genetics ; Adult ; Aged ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Prognosis ; Sweden

Genomic Correlations for Clinical Outcomes in HER2-positive Advanced Gastric Cancer Treated Using Trastuzumab-based Therapy.

Autoren: Lee SY Hyung J Kim HD et al.

Quelle: Anticancer research [Anticancer Res] 2025 Dec; Vol. 45 (12), pp. 5675-5688.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model: Print Cited Medium: Internet ISSN: 1791-7530 (Electronic) Linking ISSN: 02507005 NLM ISO Abbreviation: Anticancer Res Subsets: MEDLINE

MeSH-Schlagworte: Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/genetics , Stomach Neoplasms*/pathology , Stomach Neoplasms*/mortality , Trastuzumab*/therapeutic use , Trastuzumab*/administration & dosage , Receptor, ErbB-2*/genetics , Receptor, ErbB-2*/metabolism , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Agents, Immunological*/therapeutic use, Humans ; Male ; Female ; Middle Aged ; Aged ; Retrospective Studies ; Adult ; Treatment Outcome ; Prognosis ; Gene Amplification ; Aged, 80 and over ; Genomics ; Progression-Free Survival ; Mutation ; Biomarkers, Tumor/genetics

Hormone Receptor and HER2 Testing in Breast Cancer: Latest Questions Answered.

Autoren: Solarewicz J Allison KH

Quelle: Surgical pathology clinics [Surg Pathol Clin] 2025 Dec; Vol. 18 (4), pp. 735-750. Date of Electronic Publication: 2025 Sep 03.

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: United States NLM ID: 101491209 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1875-9157 (Electronic) Linking ISSN: 18759157 NLM ISO Abbreviation: Surg Pathol Clin Subsets: MEDLINE

MeSH-Schlagworte: Breast Neoplasms*/pathology , Breast Neoplasms*/metabolism , Breast Neoplasms*/drug therapy , Breast Neoplasms*/diagnosis , Receptor, ErbB-2*/metabolism , Receptor, ErbB-2*/analysis , Receptors, Estrogen*/metabolism , Receptors, Estrogen*/analysis , Biomarkers, Tumor*/metabolism , Biomarkers, Tumor*/analysis , Receptors, Progesterone*/metabolism , Receptors, Progesterone*/analysis, Humans ; Female ; Immunohistochemistry

Oligoclonal anti-HER2 nanobody-targeted exosomes as a nano carrier for doxorubicin delivery to HER2-positive breast cancer in vitro and in vivo.

Autoren: Al-Khafaji MK Rahbarizadeh F Ahmadvand D

Quelle: International journal of biological macromolecules [Int J Biol Macromol] 2025 Dec; Vol. 333 (Pt 2), pp. 148626. Date of Electronic Publication: 2025 Nov 08.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7909578 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0003 (Electronic) Linking ISSN: 01418130 NLM ISO Abbreviation: Int J Biol Macromol Subsets: MEDLINE

MeSH-Schlagworte: Doxorubicin*/pharmacology , Doxorubicin*/chemistry , Doxorubicin*/administration & dosage , Exosomes*/chemistry , Exosomes*/metabolism , Receptor, ErbB-2*/metabolism , Receptor, ErbB-2*/antagonists & inhibitors , Receptor, ErbB-2*/immunology , Breast Neoplasms*/drug therapy , Breast Neoplasms*/metabolism , Breast Neoplasms*/pathology , Single-Domain Antibodies*/chemistry , Drug Carriers*/chemistry, Animals ; Female ; Humans ; Mice ; Cell Line, Tumor ; Mice, Inbred BALB C ; Drug Delivery Systems

Development of Trastuzumab-coupled, siRNA encapsulating mPolyplexes targeting HER2 overexpressing cancer cells.

Autoren: Müller JT Caruso S Nguyen A et al.

Quelle: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2025 Dec; Vol. 217, pp. 114904. Date of Electronic Publication: 2025 Oct 28.

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 9109778 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3441 (Electronic) Linking ISSN: 09396411 NLM ISO Abbreviation: Eur J Pharm Biopharm Subsets: MEDLINE

MeSH-Schlagworte: Trastuzumab*/administration & dosage , Trastuzumab*/chemistry , RNA, Small Interfering*/administration & dosage , RNA, Small Interfering*/chemistry , Receptor, ErbB-2*/genetics , Receptor, ErbB-2*/metabolism , Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/genetics, Humans ; Cell Line, Tumor ; Female ; Micelles ; Polo-Like Kinase 1 ; Gene Silencing ; Antineoplastic Agents, Immunological/administration & dosage ; ErbB Receptors/genetics

Immune checkpoint inhibitors with trastuzumab and chemotherapy in advanced HER2-positive gastric cancer: A systematic review and meta-analysis.

Autoren: de Moraes FCA Moreira Rego LHR de Paiva FA et al.

Quelle: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2025 Dec; Vol. 216, pp. 104975. Date of Electronic Publication: 2025 Oct 02.

Publikationsart: Journal Article; Systematic Review; Meta-Analysis; Review

Info zur Zeitschrift: Publisher: Elsevier Scientific Publishers Country of Publication: Netherlands NLM ID: 8916049 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0461 (Electronic) Linking ISSN: 10408428 NLM ISO Abbreviation: Crit Rev Oncol Hematol Subsets: MEDLINE

MeSH-Schlagworte: Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/metabolism , Stomach Neoplasms*/mortality , Stomach Neoplasms*/pathology , Trastuzumab*/therapeutic use , Trastuzumab*/administration & dosage , Receptor, ErbB-2*/metabolism , Receptor, ErbB-2*/antagonists & inhibitors , Immune Checkpoint Inhibitors*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans

Clinical and molecular characteristics of HER2-low triple-negative breast cancer: insights from multi-omics analysis.

Autoren: Yang Y Pan L Zhou W et al.

Quelle: Breast (Edinburgh, Scotland) [Breast] 2025 Dec; Vol. 84, pp. 104584. Date of Electronic Publication: 2025 Sep 21.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9213011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3080 (Electronic) Linking ISSN: 09609776 NLM ISO Abbreviation: Breast Subsets: MEDLINE

MeSH-Schlagworte: Triple Negative Breast Neoplasms*/genetics , Triple Negative Breast Neoplasms*/pathology , Triple Negative Breast Neoplasms*/metabolism , Triple Negative Breast Neoplasms*/mortality , Receptor, ErbB-2*/genetics , Receptor, ErbB-2*/metabolism, Humans ; Female ; Middle Aged ; Class I Phosphatidylinositol 3-Kinases/genetics ; Receptors, Androgen/genetics ; Receptors, Androgen/metabolism ; Adult ; Exome Sequencing ; Mutation ; Prognosis ; Aged ; Biomarkers, Tumor/genetics ; Multiomics

Inhibition of ErbB2 mitigates secondary denervation after traumatic muscle injury.

Autoren: Sorensen JR Hoffman DB Raymond-Pope CJ et al.

Quelle: The Journal of physiology [J Physiol] 2025 Dec; Vol. 603 (23), pp. 7531-7548. Date of Electronic Publication: 2025 Mar 03.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Cambridge Univ. Press Country of Publication: England NLM ID: 0266262 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1469-7793 (Electronic) Linking ISSN: 00223751 NLM ISO Abbreviation: J Physiol Subsets: MEDLINE

MeSH-Schlagworte: Receptor, ErbB-2*/antagonists & inhibitors , Receptor, ErbB-2*/metabolism , Muscle, Skeletal*/innervation , Muscle, Skeletal*/injuries , Muscle, Skeletal*/drug effects , Muscle, Skeletal*/metabolism , Trastuzumab*/pharmacology , Trastuzumab*/therapeutic use, Animals ; Male ; Rats ; Rats, Inbred Lew ; Neuromuscular Junction/drug effects ; Neuromuscular Junction/physiology ; Neuregulin-1/metabolism

Reproducibility of Equivocal HER2 In Situ Hybridization Groups 3 and 4, and Comparison With HER2 mRNA Expression: The Thin Line Between Amplified and Nonamplified Breast Cancers.

Autoren: Baez-Navarro X Riggi J Zylberberg D et al.

Quelle: Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2025 Dec 01; Vol. 149 (12), pp. 1093-1100.

Publikationsart: Journal Article; Comparative Study

Info zur Zeitschrift: Publisher: College of American Pathologists Country of Publication: United States NLM ID: 7607091 Publication Model: Print Cited Medium: Internet ISSN: 1543-2165 (Electronic) Linking ISSN: 00039985 NLM ISO Abbreviation: Arch Pathol Lab Med Subsets: MEDLINE

MeSH-Schlagworte: Breast Neoplasms*/genetics , Breast Neoplasms*/metabolism , Breast Neoplasms*/pathology , Breast Neoplasms*/diagnosis , Receptor, ErbB-2*/genetics , Receptor, ErbB-2*/metabolism , RNA, Messenger*/metabolism , RNA, Messenger*/genetics , In Situ Hybridization*/methods, Humans ; Female ; Reproducibility of Results ; Immunohistochemistry ; Gene Amplification ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Middle Aged ; Adult ; Aged

ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34.

Autoren: Kacerovsky-Strobl S Deutschmann C Hlauschek D et al.

Quelle: Breast (Edinburgh, Scotland) [Breast] 2025 Dec; Vol. 84, pp. 104633. Date of Electronic Publication: 2025 Oct 30.

Publikationsart: Journal Article; Randomized Controlled Trial

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9213011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3080 (Electronic) Linking ISSN: 09609776 NLM ISO Abbreviation: Breast Subsets: MEDLINE

MeSH-Schlagworte: Breast Neoplasms*/pathology , Breast Neoplasms*/genetics , Breast Neoplasms*/metabolism , Breast Neoplasms*/therapy , Receptor, ErbB-2*/genetics , Receptor, ErbB-2*/metabolism , Receptor, ErbB-2*/analysis , Ki-67 Antigen*/genetics , Ki-67 Antigen*/metabolism , Ki-67 Antigen*/analysis , Estrogen Receptor alpha*/genetics , Estrogen Receptor alpha*/metabolism , Estrogen Receptor alpha*/analysis, Humans ; Female ; RNA, Messenger/metabolism ; RNA, Messenger/analysis ; Middle Aged ; Biomarkers, Tumor/metabolism ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/analysis ; Receptors, Progesterone/genetics ; Receptors, Progesterone/metabolism ; Immunohistochemistry ; Adult ; Aged ; Biopsy, Large-Core Needle

Next-generation sequencing identifies potential mechanisms of primary resistance to trastuzumab-containing therapies in HER2-positive gastric cancer: Analysis based on real-world data and online databases.

Autoren: Zhang X Liu N Song S et al.

Quelle: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2555502. Date of Electronic Publication: 2025 Sep 09.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE

MeSH-Schlagworte: Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/genetics , Receptor, ErbB-2*/genetics , Receptor, ErbB-2*/metabolism , Trastuzumab*/therapeutic use , Drug Resistance, Neoplasm*/genetics , Antineoplastic Agents, Immunological*/therapeutic use, Humans ; Female ; High-Throughput Nucleotide Sequencing ; Middle Aged ; Retrospective Studies ; Male ; Aged ; Adult ; Biomarkers, Tumor/genetics

Molecular features influencing clinical outcome of advanced HER2-positive gastric cancer receiving trastuzumab plus chemotherapy.

Autoren: Lei Y He D Si J et al.

Quelle: Annals of medicine [Ann Med] 2025 Dec; Vol. 57 (1), pp. 2581815. Date of Electronic Publication: 2025 Nov 06.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8906388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2060 (Electronic) Linking ISSN: 07853890 NLM ISO Abbreviation: Ann Med Subsets: MEDLINE

MeSH-Schlagworte: Stomach Neoplasms*/drug therapy , Stomach Neoplasms*/genetics , Stomach Neoplasms*/mortality , Stomach Neoplasms*/pathology , Trastuzumab*/therapeutic use , Trastuzumab*/administration & dosage , Receptor, ErbB-2*/metabolism , Receptor, ErbB-2*/genetics , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Female ; Middle Aged ; Male ; Aged ; Adult ; Progression-Free Survival ; Mutation ; Treatment Outcome ; Gene Amplification ; Poly-ADP-Ribose Binding Proteins/genetics ; Antineoplastic Agents, Immunological/therapeutic use

Anti-HER2 plus endocrine therapy versus anti-HER2 plus chemotherapy in hormone receptor-positive and HER2-positive metastatic breast cancer: a retrospective study.

Autoren: Fan Z Yuan Y Chen X et al.

Quelle: International journal of clinical oncology [Int J Clin Oncol] 2025 Dec; Vol. 30 (12), pp. 2532-2540. Date of Electronic Publication: 2025 Oct 09.

Publikationsart: Journal Article; Comparative Study

Info zur Zeitschrift: Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 9616295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1437-7772 (Electronic) Linking ISSN: 13419625 NLM ISO Abbreviation: Int J Clin Oncol Subsets: MEDLINE

MeSH-Schlagworte: Breast Neoplasms*/drug therapy , Breast Neoplasms*/pathology , Breast Neoplasms*/metabolism , Receptor, ErbB-2*/antagonists & inhibitors , Receptor, ErbB-2*/metabolism , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Female ; Retrospective Studies ; Middle Aged ; Adult ; Aged ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism ; Aged, 80 and over ; Neoplasm Metastasis

Enhanced computational strategies for categorizing HER2 kinase domain variants of uncertain significance through structural and functional analysis.

Autoren: Loganathan T Doss CGP

Quelle: Mammalian genome : official journal of the International Mammalian Genome Society [Mamm Genome] 2025 Dec; Vol. 36 (4), pp. 1260-1277. Date of Electronic Publication: 2025 Oct 10.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Springer-Verlag Country of Publication: United States NLM ID: 9100916 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1777 (Electronic) Linking ISSN: 09388990 NLM ISO Abbreviation: Mamm Genome Subsets: MEDLINE

MeSH-Schlagworte: Receptor, ErbB-2*/genetics , Receptor, ErbB-2*/chemistry , Receptor, ErbB-2*/metabolism , Computational Biology*/methods, Humans ; Molecular Dynamics Simulation ; Protein Domains ; Mutation ; Algorithms

Upper Respiratory Tract Infection Associated with Anti-HER2 Antibody Blockade for HER2-Positive Breast Cancer: A Bayesian Disproportionality Analysis Using Data From the FDA Adverse Event Reporting System.

Autoren: Zhao J Yang Y Chen X et al.

Quelle: Clinical therapeutics [Clin Ther] 2025 Dec; Vol. 47 (12), pp. 1155-1160. Date of Electronic Publication: 2025 Oct 09.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Excerpta Medica Country of Publication: United States NLM ID: 7706726 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-114X (Electronic) Linking ISSN: 01492918 NLM ISO Abbreviation: Clin Ther Subsets: MEDLINE

MeSH-Schlagworte: Breast Neoplasms*/drug therapy , Receptor, ErbB-2*/antagonists & inhibitors , Receptor, ErbB-2*/immunology , Respiratory Tract Infections*/chemically induced , Respiratory Tract Infections*/epidemiology , Antineoplastic Agents, Immunological*/adverse effects, Humans ; Female ; United States/epidemiology ; Adverse Drug Reaction Reporting Systems/statistics & numerical data ; Middle Aged ; United States Food and Drug Administration ; Antibodies, Monoclonal, Humanized/adverse effects ; Trastuzumab/adverse effects ; Bayes Theorem ; Adult ; Aged ; Incidence ; Ado-Trastuzumab Emtansine/adverse effects ; Immunoconjugates/adverse effects

Human epidermal growth factor receptor 2 targeted agents in gynecologic cancers: an updated review.

Autoren: Gee-Rodriguez K Indorf A Swisher EM et al.

Quelle: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2025 Dec; Vol. 35 (12), pp. 101948. Date of Electronic Publication: 2025 May 23.

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: United States NLM ID: 9111626 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-1438 (Electronic) Linking ISSN: 1048891X NLM ISO Abbreviation: Int J Gynecol Cancer Subsets: MEDLINE

MeSH-Schlagworte: Receptor, ErbB-2*/antagonists & inhibitors , Receptor, ErbB-2*/metabolism , Genital Neoplasms, Female*/drug therapy , Genital Neoplasms, Female*/metabolism , Antineoplastic Agents*/therapeutic use, Humans ; Female ; Molecular Targeted Therapy/methods

HER2 testing in multifocal/multicentric breast cancer: should all foci be tested in the context of HER2-low and HER2-ultralow?

Autoren: Wu S Liu H Wang T et al.

Quelle: Breast (Edinburgh, Scotland) [Breast] 2025 Dec; Vol. 84, pp. 104572. Date of Electronic Publication: 2025 Sep 13.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9213011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3080 (Electronic) Linking ISSN: 09609776 NLM ISO Abbreviation: Breast Subsets: MEDLINE

MeSH-Schlagworte: Breast Neoplasms*/pathology , Breast Neoplasms*/metabolism , Breast Neoplasms*/genetics , Receptor, ErbB-2*/metabolism , Receptor, ErbB-2*/analysis , Neoplasms, Multiple Primary*/pathology , Neoplasms, Multiple Primary*/metabolism, Humans ; Female ; Retrospective Studies ; Middle Aged ; Aged ; Adult ; Biomarkers, Tumor/metabolism ; Biomarkers, Tumor/analysis ; Trastuzumab/therapeutic use ; Aged, 80 and over

A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors.

Autoren: Cortés J Priego A Garralda E et al.

Quelle: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Dec 01; Vol. 31 (23), pp. 4953-4963.

Publikationsart: Journal Article; Clinical Trial, Phase I

Info zur Zeitschrift: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

MeSH-Schlagworte: Receptor, ErbB-2*/metabolism , Receptor, ErbB-2*/antagonists & inhibitors , Receptor, ErbB-2*/genetics , Receptors, IgG*/antagonists & inhibitors , Receptors, IgG*/immunology , Antibodies, Monoclonal*/administration & dosage , Antibodies, Monoclonal*/adverse effects , Neoplasms*/drug therapy , Neoplasms*/pathology , Neoplasms*/metabolism , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Animals ; Female ; Middle Aged ; Mice ; Aged ; Male ; Adult ; Trastuzumab/administration & dosage ; Maximum Tolerated Dose ; Xenograft Model Antitumor Assays ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology